CN105659087B - 筛选靶向靶生物实体的候选生物实体的方法 - Google Patents

筛选靶向靶生物实体的候选生物实体的方法 Download PDF

Info

Publication number
CN105659087B
CN105659087B CN201480045112.7A CN201480045112A CN105659087B CN 105659087 B CN105659087 B CN 105659087B CN 201480045112 A CN201480045112 A CN 201480045112A CN 105659087 B CN105659087 B CN 105659087B
Authority
CN
China
Prior art keywords
shg
signal
candidate
target
biochemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480045112.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105659087A (zh
Inventor
约书亚·萨拉夫斯基
卡尔·本顿·莫里三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blu Ray Therapy Co
Original Assignee
Biodesy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesy Inc filed Critical Biodesy Inc
Publication of CN105659087A publication Critical patent/CN105659087A/zh
Application granted granted Critical
Publication of CN105659087B publication Critical patent/CN105659087B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201480045112.7A 2013-06-13 2014-06-13 筛选靶向靶生物实体的候选生物实体的方法 Active CN105659087B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834782P 2013-06-13 2013-06-13
US61/834,782 2013-06-13
PCT/US2014/042428 WO2014201435A1 (en) 2013-06-13 2014-06-13 Method of screening candidate biochemical entities targeting a target biochemical entity

Publications (2)

Publication Number Publication Date
CN105659087A CN105659087A (zh) 2016-06-08
CN105659087B true CN105659087B (zh) 2019-09-17

Family

ID=52022828

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480045112.7A Active CN105659087B (zh) 2013-06-13 2014-06-13 筛选靶向靶生物实体的候选生物实体的方法

Country Status (6)

Country Link
US (1) US20150330990A1 (https=)
EP (1) EP3008465B1 (https=)
JP (2) JP6518656B2 (https=)
CN (1) CN105659087B (https=)
GB (1) GB2538216A (https=)
WO (1) WO2014201435A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US9428789B2 (en) 2011-03-21 2016-08-30 Biodesy, Inc. Classification of kinase inhibitors using nonlinear optical techniques
GB2520111A (en) 2012-02-05 2015-05-13 Biodesy Inc Methods for identifying modulators of Ras using nonlinear techniques
US20130288271A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of protein
US9395358B2 (en) 2012-02-05 2016-07-19 Biodesy, Inc. Methods for detecting allosteric modulators of protein
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
WO2016003936A1 (en) 2014-06-30 2016-01-07 Biodesy, Inc. Systems and methods for high throughput analysis of conformation in biological entities
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EP3237906B8 (en) * 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
EP3278087A4 (en) 2015-04-02 2018-12-19 Biodesy, Inc. Methods for determining protein structure using a surface-selective nonlinear optical technique
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3353547A1 (en) * 2015-09-22 2018-08-01 Delta TM Technologies Designing customized protein-specific buffer systems
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
JP2018533939A (ja) * 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2017196891A1 (en) 2016-05-09 2017-11-16 Biodesy, Inc. Methods and devices for detection of peripheral membrane protein interactions using nonlinear optical techniques
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
CN106650209B (zh) * 2016-09-30 2020-07-07 中车南京浦镇车辆有限公司 一种车辆应用实时信息确定可靠性增长趋势及参数的方法
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
CN106650317B (zh) * 2016-10-09 2019-04-16 南京双运生物技术有限公司 一种通过协同过滤公共数据库发现肿瘤潜在基因标靶的方法
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EA201992476A1 (ru) * 2017-04-18 2020-02-25 Икс-Чем, Инк. Способы идентификации соединений
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US10657525B2 (en) 2017-06-27 2020-05-19 Kasisto, Inc. Method and apparatus for determining expense category distance between transactions via transaction signatures
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
EP4045920A4 (en) * 2019-10-15 2023-10-11 Jnana Therapeutics Inc. INTERACTION DISCOVERY PLATFORM WITH A REACTIVE AFFINITY PROBE
CN112630444B (zh) * 2020-12-11 2024-05-24 深圳碳云智肽药物科技有限公司 基于靶点蛋白的多肽筛选方法
CN113963745A (zh) * 2021-12-07 2022-01-21 国际竹藤中心 一种构建植物发育分子调控网络的方法及其应用
CN114317669A (zh) * 2022-01-04 2022-04-12 北京大学 一种基于细胞内蛋白激酶c激活状态筛选药物的方法及高通量筛选装置
WO2024129721A1 (en) * 2022-12-13 2024-06-20 Lafond David Systems and methods to predict biological receptor signal response

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505798A (ja) * 1996-02-01 2000-05-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド コルチコトロピン放出因子の内因性レベルを上昇させる方法
JP2004523726A (ja) * 2000-07-12 2004-08-05 カロ バイオ ユー エス エイ，インコーポレイテッド コンフォメーションに敏感な結合ペプチドの同定方法およびその利用
US20020094528A1 (en) * 2000-11-29 2002-07-18 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations
US20030129649A1 (en) * 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US20030148391A1 (en) * 2002-01-24 2003-08-07 Salafsky Joshua S. Method using a nonlinear optical technique for detection of interactions involving a conformational change
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP1637885A1 (en) 2004-09-16 2006-03-22 Vivalis Method of screening by using conformation sensitive peptides
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
JP2008544252A (ja) * 2005-06-16 2008-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経変性疾患のための潜在的薬物分子の同定における、アミロイドベータタンパク質チャネルその、構造および使用
US20090010894A1 (en) * 2005-12-23 2009-01-08 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
WO2008013859A2 (en) * 2006-07-28 2008-01-31 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
EP2326728A1 (en) * 2008-07-24 2011-06-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Fluorescently or spin-labeled kinases for rapid screening and identification of novel kinase inhibitor scaffolds
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2010031185A1 (en) * 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US9428789B2 (en) * 2011-03-21 2016-08-30 Biodesy, Inc. Classification of kinase inhibitors using nonlinear optical techniques
GB2517857A (en) * 2012-04-25 2015-03-04 Biodesy Inc Methods for detecting allosteric modulators of proteins

Also Published As

Publication number Publication date
WO2014201435A1 (en) 2014-12-18
CN105659087A (zh) 2016-06-08
EP3008465A4 (en) 2017-02-15
EP3008465B1 (en) 2019-08-07
GB2538216A (en) 2016-11-16
JP6518656B2 (ja) 2019-05-22
JP2019135498A (ja) 2019-08-15
JP2016527486A (ja) 2016-09-08
US20150330990A1 (en) 2015-11-19
EP3008465A1 (en) 2016-04-20
WO2014201435A8 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
CN105659087B (zh) 筛选靶向靶生物实体的候选生物实体的方法
CN106290917B (zh) 用于检测蛋白质的变构调节剂的方法
Renaud et al. Biophysics in drug discovery: impact, challenges and opportunities
US9383361B2 (en) Methods for detecting allosteric modulators of protein
US9428789B2 (en) Classification of kinase inhibitors using nonlinear optical techniques
Turk Understanding and exploiting substrate recognition by protein kinases
US20160356767A1 (en) Methods for detecting allosteric modulators of protein
Kool et al. Studying protein–protein affinity and immobilized ligand–protein affinity interactions using MS-based methods
Mons et al. Technologies for direct detection of covalent protein–drug adducts
WO2013115867A1 (en) Methods for identifying modulators of ras using nonlinear techniques
JP2011528560A (ja) 新規キナーゼ阻害剤足場の迅速なスクリーニングおよび同定のための蛍光標識またはスピン標識キナーゼ
JP2010540947A (ja) 細胞内標的タンパクに結合する小分子の全プロテオーム定量
Petri et al. Size-dependent target engagement of covalent probes
Morandell et al. QIKS–Quantitative identification of kinase substrates
Valtonen LES U N IV ERSITATIS TU RK
Roberto et al. NMR Screening Methods in Fragment-Based Drug Discovery
Shraga First of Their Kind Covalent Chemical Probes Targeting Kinases (MKK7/BTK) For Inhibition or Degradation
Auld et al. Literature Search and Review
Ivan Bifunctional inhibitors and photoluminescent probes for studies on protein complexes
Zeng Development of Novel Technologies for Interactome Detection
Valtonen Label-free methods for studying protein-protein interactions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Blu ray therapy company

Address before: California, USA

Patentee before: BIODESY, Inc.

CP01 Change in the name or title of a patent holder